AGP Executive Report
Last update: an hour agoClinical CBD/THC Update: A Phase II LiBBY trial reported that a rapid-acting THC/CBD oral oil significantly reduced agitation in late-stage dementia patients, with benefits lasting to 12 weeks. Sleep Cannabinoids: A new explainer breaks down CBN’s real-world role in sleep products, noting it’s a minor cannabinoid that may be mildly calming but isn’t a guaranteed “sleep switch,” especially when formulas mix multiple ingredients. Public Health & Safety: Virginia launched a statewide tip line and online form for suspected illegal cannabis activity ahead of its regulated market rollout. Regulatory/Market Watch: Colorado regulators issued a recall for concentrate after banned pesticide chlorfenapyr was found in additional testing. Policy Momentum: U.S. Senate leaders reintroduced the Cannabis Administration and Opportunity Act to end federal marijuana criminalization and reinvest in communities. Industry/Access: Arkansas medical marijuana sales hit $140.3M in the first half of 2026, with active patient cards rising to 119,074. International Courts: Kenya’s High Court rejected a Rastafari bid for a cannabis exemption.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
